Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMA102 Injection Monotherapy in Type 2 Diabetes Mellitus
CTR20211661Phase 3Completed
- Sponsor
- Gmax Biopharm
- Start
- Jul 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of glutazumab in type 2 diabetes mellitus (T2DM), sponsored by Gmax Biopharm. Started Jul 2021; status: completed.
02
Drugs
glutazumab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20211661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211661.